US5613982A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of preparing transplant tissue to reduce immunogenicity upon implantation
Assignee: Artivion Inc
•
Filing: 1995-06-05
•
Granted: 1997-03-25
•
Expires: 2015-06-05
Abstract
Abstract This disclosure includes a method for generating a functional hybrid bioprosthesis. Tissue formed naturally of interstitial collagens is treated to kill native cells and remove potentially immunologically active soluble molecules. Then it may be treated sequentially with extracellular matrix adhesion factor such as fibronectin, extracellular matrix glycosaminoglycan such as heparin, and growth factor appropriate to the cell type required to function within the matrix, and incubating the transplant tissue matrix with cells that are either allogeneic or autologous for the recipient thereby imparting to the matrix the characteristics of the cell type and tissue selected. Tissues with a variety of functional bioactivities can thus be formed in vitro prior to graft transplantation or implantation which will exhibit reduced or no stimulation of an immunological response in the recipient.
Inventors
- 👤 Steven Goldstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:24
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3683; A61L27/3687; A61L27/3604; A61L27/3625; A61L27/38; A61L27/3804; A61L27/3895; A61L27/50; A61L27/507; A61L2430/00; A61L2430/40; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
134 words
An in vitro process for generating implants or grafts of collagenous, connective, or vascular tissue which are xenogeneic to a human recipient comprising decellularizing a natural tissue to produce a tissue matrix, the tissue matrix is next washed to remove cellular antigens, or extracellular antigens, or both, followed by treatment of the tissue matrix with adhesion factors comprised of fibronectin and heparin effective to promote attachment thereto of fibroblast cells immunologically acceptable to the implant or graft recipient, next the tissue matrix is treated with adhesion factor and is repopulated by incubating the matrix in the presence of the fibroblast cells and fibroblast growth factor until such cellular repopulation provides a vitalized tissue histologically similar to the corresponding natural tissue, and wherein the implant tissue generated is mechanically, biochemically and immunologically suitable for implantation.
Claim 2
Dependent Claim
134 words
An in vitro process for generating implants or grafts of collagenous, connective, or vascular tissue which are xenogeneic to a human recipient comprising decellularizing a natural tissue to produce a tissue matrix, the tissue matrix is next washed to remove cellular antigens, or extracellular antigens, or both, followed by treatment of the tissue matrix with adhesion factors comprised of fibronectin and heparin effective to promote attachment thereto of fibroblast cells immunologically acceptable to the implant or graft recipient, next the tissue matrix is treated with adhesion factor and is repopulated by incubating the matrix in the presence of the fibroblast cells and fibroblast growth factor until such cellular repopulation provides a vitalized tissue histologically similar to the corresponding natural tissue, and wherein the implant tissue generated is mechanically, biochemically and immunologically suitable for implantation.
Claim 3
Dependent Claim
16 words
The process of claim 1 wherein the fibronectin comprises human plasma fibronectin or human tissue fibronectin.
Claim 4
Dependent Claim
12 words
The process of claim 2 wherein the natural tissue is collagenous tissue.
Claim 5
Dependent Claim
12 words
The process of claim 2 wherein the natural tissue is connective tissue.
Claim 6
Dependent Claim
14 words
The process of claim 3 wherein the fibroblast cells are cultured human fibroblast cells.
Claim 7
Dependent Claim
22 words
The process of claim 5 wherein the natural tissue is heart valve tissue, and wherein the repopulation cells are human fibroblast cells.
Claim 8
Dependent Claim
23 words
The process of claim 1 further comprising the step of cryopreserving the tissue matrix at a stage prior to the cellular repopulation step.
Claim 9
Dependent Claim
26 words
The process of claim 4 wherein the natural tissue is decellularized by treatments including treatment with nucleases so as to limit generation of new immunological sites.
Claim 10
Dependent Claim
28 words
The process of claim 1 wherein the heparin adheres fibronectin to portions of the tissue matrix, and wherein the fibroblast-growth factor is basic human recombinant fibroblast growth factor.
Claim 11
Dependent Claim
16 words
The process of claim 9 wherein the natural tissue is aortic or pulmonary heart valve tissue.
Claim 12
Dependent Claim
12 words
The process of claim 1 wherein the fibroblast cells are autogenous cells.
Claim 13
Dependent Claim
12 words
The process of claim 1 wherein the fibroblast cells are allogenous cells.
Claim 14
Dependent Claim
15 words
The process of claim 1 wherein the fibroblast cells are derived from stable cell lines.
Claim 15
Dependent Claim
21 words
The process of claim 1 wherein the fibroblast cells are modified genetically by techniques of stable transfection with exogenous genetic material.
Claim 16
Dependent Claim
22 words
The process of claim 1 wherein the fibroblast cells are of human origin and are modified to be substantially non-immunogenic upon implantation.
Claim 17
Dependent Claim
20 words
The process of claim 1 wherein the fibroblast cells are of human origin and are modified to express specific proteins.
Claim 18
Dependent Claim
65 words
The process of claim 1 wherein the tissue is of porcine or bovine origin, the adhesion matrix factor comprises purified fibronectin and heparin, and wherein the repopulating cells are human fibroblast cells in the presence of effective amounts of basic or acid fibroblast growth factor and the implant tissue produced is a xenogeneic implant substantially free of adverse immunological response upon implantation into a human.
Claim 19
Dependent Claim
21 words
The process of claim 1 wherein the decellularization step comprises treating the tissues with a low ionic strength solution and nucleases.
Claim 20
Dependent Claim
33 words
The process of claim 18 wherein the low ionic strength solution of nucleases includes at least one member selected from the group consisting of RNAase A, DNAase I, EcoR I and Hind III.
Claim 21
Dependent Claim
116 words
The process of claim 1 wherein the natural tissue is collagenous tissue; the tissue is decellularized by treatment with a low ionic strength solution and DNAase I and RNAase A, effective to eliminate native cells and provide a tissue matrix of limited immunogenicity; and the tissue matrix is treated with an amount of a buffered solution containing fibronectin and heparin sulfate effective to provide sites associated with the tissue matrix which facilitate fibroblast cell attachment thereto; and wherein the tissue matrix is repopulated by incubating it together with fibroblast cells of human origin in the presence of an amount of fibroblast growth factor, effective to facilitate cell growth and repopulate the tissue matrix with fibroblast cells.
References Cited (Backward Citations)
FR1522286A
Cited
FR2104349A5
Cited
US3966401A
Cited
US4240794A
Cited
US4383832A
Cited
US4378224A
Cited
US4407787A
Cited
US4539716A
Cited
US4323358A
Cited
US4546500A
Cited
US4485096A
Cited
WO1983003335A1
Cited
US4648881A
Cited
US4647283A
Cited
US4405327A
Cited
US4402697A
Cited
US4973493A
Cited
US5215541A
Cited
WO1984001879A1
Cited
US4559298A
Cited
GB2136533A
Cited
US4642120A
Cited
US4801299A
Cited
EP0128706A2
Cited
US4865871A
Cited
US4799361A
Cited
US4567847A
Cited
US4609551A
Cited
US4553974A
Cited
WO1986002273A1
Cited
US4785079A
Cited
US4828563A
Cited
FR2589165A1
Cited
US4688387A
Cited
US4911710A
Cited
US4776853A
Cited
WO1988002263A1
Cited
US4798611A
Cited
EP0267026A2
Cited
US4707998A
Cited
US4902782A
Cited
US4890457A
Cited
US4835102A
Cited
US4838888A
Cited
EP0296475A1
Cited
WO1989000198A1
Cited
US4870160A
Cited
WO1989001286A1
Cited
US5294551A
Cited
US4878913A
Cited
WO1989008117A1
Cited
US4950483A
Cited
US4960424A
Cited
EP0361957A1
Cited
US5002566A
Cited
US4964280A
Cited
US5131850A
Cited
WO1991016009A1
Cited
WO1991018505A1
Cited
US5145770A
Cited
US5336616A
Cited
US5197985A
Cited
US5192312A
Cited
US5512474A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-03-24 | 2000-09-23 | 2001-03-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-03-24 | 2004-09-23 | 2005-03-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-03-24 | 2008-09-23 | 2009-03-25 | $7700.00 | Window Closed / Lapsed |